The 36-month beta value for CABA is at 2.41. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 5 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CABA is 41.14M, and currently, shorts hold a 15.54% of that float. The average trading volume for CABA on October 09, 2024 was 1.03M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CABA) stock’s latest price update
The stock price of Cabaletta Bio Inc (NASDAQ: CABA) has jumped by 8.23 compared to previous close of 4.01. Despite this, the company has seen a fall of -6.47% in its stock price over the last five trading days. globenewswire.com reported 2024-09-25 that PHILADELPHIA, Sept. 25, 2024 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced two presentations at the upcoming American College of Rheumatology (ACR) Convergence 2024, which is being held at the Walter E. Washington Convention Center in Washington, D.C. from November 14-19, 2024. The presentations will feature new and updated clinical data on CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, which is being evaluated in multiple ongoing clinical trials in the RESET™ clinical development program.
CABA’s Market Performance
Cabaletta Bio Inc (CABA) has experienced a -6.47% fall in stock performance for the past week, with a -1.36% drop in the past month, and a -44.99% drop in the past quarter. The volatility ratio for the week is 9.70%, and the volatility levels for the past 30 days are at 10.02% for CABA. The simple moving average for the last 20 days is 1.06% for CABA’s stock, with a simple moving average of -66.81% for the last 200 days.
Analysts’ Opinion of CABA
Many brokerage firms have already submitted their reports for CABA stocks, with Jefferies repeating the rating for CABA by listing it as a “Buy.” The predicted price for CABA in the upcoming period, according to Jefferies is $36 based on the research report published on February 05, 2024 of the current year 2024.
William Blair, on the other hand, stated in their research note that they expect to see CABA reach a price target of $38. The rating they have provided for CABA stocks is “Outperform” according to the report published on November 29th, 2023.
Cantor Fitzgerald gave a rating of “Overweight” to CABA, setting the target price at $40 in the report published on October 24th of the previous year.
CABA Trading at -12.29% from the 50-Day Moving Average
After a stumble in the market that brought CABA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.53% of loss for the given period.
Volatility was left at 10.02%, however, over the last 30 days, the volatility rate increased by 9.70%, as shares sank -2.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.70% lower at present.
During the last 5 trading sessions, CABA fell by -6.47%, which changed the moving average for the period of 200-days by -79.60% in comparison to the 20-day moving average, which settled at $4.29. In addition, Cabaletta Bio Inc saw -80.88% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CABA starting from Binder Gwendolyn, who sale 11,000 shares at the price of $19.59 back on Jan 19 ’24. After this action, Binder Gwendolyn now owns 20,000 shares of Cabaletta Bio Inc, valued at $215,439 using the latest closing price.
Binder Gwendolyn, the of Cabaletta Bio Inc, sale 11,000 shares at $21.89 during a trade that took place back on Dec 19 ’23, which means that Binder Gwendolyn is holding 20,000 shares at $240,789 based on the most recent closing price.
Stock Fundamentals for CABA
Current profitability levels for the company are sitting at:
- -24.97 for the present operating margin
- 0.62 for the gross margin
The net margin for Cabaletta Bio Inc stands at -22.44. The total capital return value is set at -0.5. Equity return is now at value -48.16, with -44.76 for asset returns.
Based on Cabaletta Bio Inc (CABA), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -9.98. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -90.86.
Currently, EBITDA for the company is -73.23 million with net debt to EBITDA at 1.73. When we switch over and look at the enterprise to sales, we see a ratio of 10.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.52.
Conclusion
In conclusion, Cabaletta Bio Inc (CABA) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
